October 17, 2022 in Kineta Press Release

Kineta Announces Clinical Collaboration with Merck to Evaluate KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Cancer Patients with Advanced Solid Tumors

Kineta’s VISTA blocking immunotherapy KVA12123 (formerly referred to as KVA12.1) to be evaluated in patients with advanced solid tumors Clinical trial anticipated to begin in late 2022 Seattle, ...

Read More